Inventiva Sa (IVA)

Inventiva S.A. (IVA) is a highly innovative clinical-stage biopharmaceutical company well-regarded for its dedicated efforts in developing novel therapies for diseases with significant unmet medical need. Established in 2012 and based in France, IVA has successfully carved a distinct name for itself in the global healthcare sector, typically holding the banner for path-breaking science and pioneering medical research.

At the heart of Inventiva's operation is the will to develop a diversified and robust pipeline of drugs. The company is renowned for its foray into a range of diseases, primarily focusing on areas such as NASH (Non-Alcoholic Steatohepatitis), systemic sclerosis, and mucopolysaccharidosis (MPS). Inventiva's lead candidate, lanifibranor, is targeted towards the potential treatment of NASH, a liver disease affecting an estimated 20-30% of the global population.

Inventiva's business objective is prominently centred around creating ground-breaking treatment options for diseases with limited therapeutic choices. As a fervent believer in innovation and progress, the company carries out meticulous scientific research, continually expanding the boundaries of our knowledge in the bioscience and medical sectors.

The company is built on robust pillars of insight, knowledge, collaboration, and the conviction to transform patients' lives. It tends to advance towards clinical and strategic partnerships, seeking to cooperate with other leading biotech and pharmaceutical firms to create the best healthcare solutions.

Inventiva's development strategy is patient-centric, aiming to provide effective and transformative therapies. The company's progress underlines its commitment to discovering, developing, and commercializing innovative drugs that drastically alter the course of severe diseases. Notably, it regards the unique and proprietary technology platform as a key strategic asset to achieving its business objectives.

Inventiva S.A. has cemented its status as a leader, bolstered by a versatile team of world-class scientists and seasoned professionals with extensive experience in drug development. It also prides itself on its strong financial health, having had successful initial public offering (IPO) on Euronext Paris and is also listed on the NASDAQ Global Market.

To sum up, Inventiva S.A. stands as an emblem of perseverance and excellence in the biopharmaceutical industry. With a relentless focus on innovation and determination to make a genuine difference in patients' lives, the company's future in creating a healthier world is promising.